

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Soriano Isabel</u> _____ (Last) (First) (Middle) <u>C/O 9341 COURTLAND DRIVE NE</u> _____ (Street) <u>ROCKFORD MI 49351</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/04/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>WOLVERINE WORLD WIDE INC /DE/ [www]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President, International</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,883 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Units	(2)	(2)	Common Stock	470	0.00 ⁽³⁾	D	
Restricted Stock Units	(4)	(4)	Common Stock	2,069	0.00 ⁽³⁾	D	
Restricted Stock Units	(5)	(5)	Common Stock	2,923	0.00 ⁽³⁾	D	
Restricted Stock Units	(6)	(6)	Common Stock	3,500	0.00 ⁽³⁾	D	
Restricted Stock Units	(7)	(7)	Common Stock	5,261	0.00 ⁽³⁾	D	
Restricted Stock Units	(8)	(8)	Common Stock	1,301	0.00 ⁽³⁾	D	

Explanation of Responses:

- The number of shares reported includes 3,204 time-vested restricted shares of Common Stock granted to the Reporting Person between July 2018 and February 2020, under the Company's Stock Incentive Plan of 2016.
- On July 30, 2018, the Reporting Person was granted 1,565 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
- Restricted stock units convert into shares of Common Stock on a one-for-one basis.
- On February 6, 2019, the Reporting Person was granted 3,448 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
- On February 5, 2020, the Reporting Person was granted 3,653 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
- On November 5, 2020, the Reporting Person was granted 3,500 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 50% on each of the first and second anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
- On February 9, 2021, the Reporting Person was granted 5,261 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
- On August 2, 2021, the Reporting Person was granted 1,301 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

/s/ David Latchana by
Power of Attorney

08/16/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned, a director and/or officer of Wolverine World Wide, Inc., a Delaware corporation ("Wolverine"), does hereby appoint KYLE L. HANSON and DAVID A. LATCHANA, or any one or more of them, with full power of substitution, his or her attorneys and agents to do any and all acts and things and to execute and file any and all documents and instruments that such attorneys and agents, or any of them, consider necessary or advisable to enable the undersigned (in his or her individual capacity or in a fiduciary or other capacity) to comply with the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any requirements of the Securities and Exchange Commission in respect thereof, in connection with his or her intended sale of any security related to Wolverine pursuant to Rule 144 issued under the Securities Act and the preparation, execution and filing of any report or statement of beneficial ownership or changes in beneficial ownership of securities of Wolverine that the undersigned (in his or her individual capacity or in a fiduciary or other capacity) may be required to file pursuant to Section 16(a) of the Exchange Act including, without limitation, full power and authority to sign the undersigned's name, in his or her individual capacity or in a fiduciary or other capacity, to any report or statement on Form 3, 4, 5 or 144, or to any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto, hereby ratifying and confirming all that such attorneys and agents, or any of them, shall do or cause to be done by virtue hereof.

The undersigned agrees that the attorneys-in-fact act as legal counsel to and/or officers of Wolverine in connection with the securities matters addressed herein, and do not represent the undersigned in his or her personal capacity in connection with such matters. The undersigned agrees that the attorneys-in-fact may rely entirely on information furnished orally or in writing by the undersigned or his or her authorized representative(s) to such attorneys-in-fact. The undersigned also agrees to indemnify and hold harmless Wolverine and the attorneys-in-fact against any losses, claims, damages or liabilities (or actions in respect thereof) that arise out of or are based upon any untrue statement or omission of necessary fact in the information provided by the undersigned or his or her authorized representative(s) to the attorneys-in-fact for purposes of executing, acknowledging, delivering or filing any such forms, or any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto. The undersigned agrees to reimburse Wolverine and the attorneys-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This authorization shall supersede all prior authorizations to act for the undersigned with respect to securities of Wolverine in these matters, which prior authorizations are hereby revoked, and shall survive the termination of the undersigned's status as a director and/or officer of Wolverine and remain in effect thereafter for so long as the undersigned (in his or her individual capacity or in a fiduciary or other capacity) is subject to Rule 144 with respect to securities of Wolverine or has any obligation under Section 16 of the Exchange Act with respect to securities of Wolverine.

Date August 9, 2021

/s/ Isabel Soriano
Signature

Isabel Soriano
Printed Name